SUPERNUS PHARMACEUTICALS INC (SUPN) Fundamental Analysis & Valuation

NASDAQ:SUPN • US8684591089

Current stock price

50.68 USD
-0.82 (-1.59%)
At close:
50.68 USD
0 (0%)
After Hours:

This SUPN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. SUPN Profitability Analysis

1.1 Basic Checks

  • SUPN had positive earnings in the past year.
  • In the past year SUPN had a positive cash flow from operations.
  • SUPN had positive earnings in 4 of the past 5 years.
  • Each year in the past 5 years SUPN had a positive operating cash flow.
SUPN Yearly Net Income VS EBIT VS OCF VS FCFSUPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

1.2 Ratios

  • SUPN has a Return On Assets of -2.65%. This is in the better half of the industry: SUPN outperforms 74.48% of its industry peers.
  • With a decent Return On Equity value of -3.63%, SUPN is doing good in the industry, outperforming 77.60% of the companies in the same industry.
  • SUPN has a better Return On Invested Capital (0.76%) than 78.13% of its industry peers.
  • SUPN had an Average Return On Invested Capital over the past 3 years of 2.78%. This is significantly below the industry average of 13.06%.
Industry RankSector Rank
ROA -2.65%
ROE -3.63%
ROIC 0.76%
ROA(3y)0.95%
ROA(5y)1.92%
ROE(3y)1.21%
ROE(5y)3.41%
ROIC(3y)2.78%
ROIC(5y)3.35%
SUPN Yearly ROA, ROE, ROICSUPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

1.3 Margins

  • SUPN's Operating Margin of 1.55% is fine compared to the rest of the industry. SUPN outperforms 78.13% of its industry peers.
  • SUPN's Operating Margin has declined in the last couple of years.
  • With an excellent Gross Margin value of 89.89%, SUPN belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.
  • SUPN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 1.55%
PM (TTM) N/A
GM 89.89%
OM growth 3Y-36.8%
OM growth 5Y-45.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.12%
GM growth 5Y0%
SUPN Yearly Profit, Operating, Gross MarginsSUPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. SUPN Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SUPN is destroying value.
  • SUPN has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for SUPN has been increased compared to 5 years ago.
  • SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SUPN Yearly Shares OutstandingSUPN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
SUPN Yearly Total Debt VS Total AssetsSUPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • SUPN has an Altman-Z score of 5.82. This indicates that SUPN is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 5.82, SUPN is doing good in the industry, outperforming 78.13% of the companies in the same industry.
  • SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.82
ROIC/WACC0.08
WACC9.16%
SUPN Yearly LT Debt VS Equity VS FCFSUPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.3 Liquidity

  • SUPN has a Current Ratio of 1.90. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
  • SUPN has a worse Current ratio (1.90) than 63.54% of its industry peers.
  • SUPN has a Quick Ratio of 1.66. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of SUPN (1.66) is worse than 60.94% of its industry peers.
Industry RankSector Rank
Current Ratio 1.9
Quick Ratio 1.66
SUPN Yearly Current Assets VS Current LiabilitesSUPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. SUPN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 8.14% over the past year.
  • SUPN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.21% yearly.
  • Looking at the last year, SUPN shows a quite strong growth in Revenue. The Revenue has grown by 8.63% in the last year.
  • SUPN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.68% yearly.
EPS 1Y (TTM)8.14%
EPS 3Y45.76%
EPS 5Y6.21%
EPS Q2Q%12%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y2.52%
Revenue growth 5Y6.68%
Sales Q2Q%21.48%

3.2 Future

  • The Earnings Per Share is expected to grow by 17.52% on average over the next years. This is quite good.
  • Based on estimates for the next years, SUPN will show a quite strong growth in Revenue. The Revenue will grow by 14.29% on average per year.
EPS Next Y-38.5%
EPS Next 2Y23.69%
EPS Next 3Y18.42%
EPS Next 5Y17.52%
Revenue Next Year23.16%
Revenue Next 2Y20.6%
Revenue Next 3Y18.26%
Revenue Next 5Y14.29%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SUPN Yearly Revenue VS EstimatesSUPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
SUPN Yearly EPS VS EstimatesSUPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

4

4. SUPN Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 15.89, SUPN is valued correctly.
  • 85.42% of the companies in the same industry are more expensive than SUPN, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of SUPN to the average of the S&P500 Index (26.78), we can say SUPN is valued slightly cheaper.
  • With a Price/Forward Earnings ratio of 25.83, SUPN can be considered very expensive at the moment.
  • 75.00% of the companies in the same industry are more expensive than SUPN, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of SUPN to the average of the S&P500 Index (23.54), we can say SUPN is valued inline with the index average.
Industry RankSector Rank
PE 15.89
Fwd PE 25.83
SUPN Price Earnings VS Forward Price EarningsSUPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • SUPN's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. SUPN is cheaper than 79.69% of the companies in the same industry.
  • SUPN's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. SUPN is cheaper than 76.56% of the companies in the same industry.
Industry RankSector Rank
P/FCF 63.45
EV/EBITDA 24.11
SUPN Per share dataSUPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • SUPN's earnings are expected to grow with 18.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)2.56
EPS Next 2Y23.69%
EPS Next 3Y18.42%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SUPN Dividend Analysis

5.1 Amount

  • SUPN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SUPN Fundamentals: All Metrics, Ratios and Statistics

SUPERNUS PHARMACEUTICALS INC

NASDAQ:SUPN (4/10/2026, 8:00:01 PM)

After market: 50.68 0 (0%)

50.68

-0.82 (-1.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners103.58%
Inst Owner Change0%
Ins Owners4.32%
Ins Owner Change1.51%
Market Cap2.92B
Revenue(TTM)718.95M
Net Income(TTM)-38.55M
Analysts83.33
Price Target64.43 (27.13%)
Short Float %7.61%
Short Ratio5.47
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)105.02%
Min EPS beat(2)67.83%
Max EPS beat(2)142.22%
EPS beat(4)4
Avg EPS beat(4)78.33%
Min EPS beat(4)15.55%
Max EPS beat(4)142.22%
EPS beat(8)7
Avg EPS beat(8)76.31%
EPS beat(12)10
Avg EPS beat(12)66.61%
EPS beat(16)11
Avg EPS beat(16)43.29%
Revenue beat(2)2
Avg Revenue beat(2)5.83%
Min Revenue beat(2)5.28%
Max Revenue beat(2)6.37%
Revenue beat(4)3
Avg Revenue beat(4)4.06%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)6.37%
Revenue beat(8)6
Avg Revenue beat(8)5.39%
Revenue beat(12)9
Avg Revenue beat(12)4.44%
Revenue beat(16)11
Avg Revenue beat(16)2.87%
PT rev (1m)2.99%
PT rev (3m)2.99%
EPS NQ rev (1m)-16.57%
EPS NQ rev (3m)11.24%
EPS NY rev (1m)-46.67%
EPS NY rev (3m)-54.71%
Revenue NQ rev (1m)-1.01%
Revenue NQ rev (3m)0.41%
Revenue NY rev (1m)0.88%
Revenue NY rev (3m)-0.23%
Valuation
Industry RankSector Rank
PE 15.89
Fwd PE 25.83
P/S 4.06
P/FCF 63.45
P/OCF 61.65
P/B 2.75
P/tB 7.94
EV/EBITDA 24.11
EPS(TTM)3.19
EY6.29%
EPS(NY)1.96
Fwd EY3.87%
FCF(TTM)0.8
FCFY1.58%
OCF(TTM)0.82
OCFY1.62%
SpS12.49
BVpS18.44
TBVpS6.38
PEG (NY)N/A
PEG (5Y)2.56
Graham Number36.38
Profitability
Industry RankSector Rank
ROA -2.65%
ROE -3.63%
ROCE 1%
ROIC 0.76%
ROICexc 1.05%
ROICexgc 7.57%
OM 1.55%
PM (TTM) N/A
GM 89.89%
FCFM 6.4%
ROA(3y)0.95%
ROA(5y)1.92%
ROE(3y)1.21%
ROE(5y)3.41%
ROIC(3y)2.78%
ROIC(5y)3.35%
ROICexc(3y)4.57%
ROICexc(5y)5.05%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)3.69%
ROCE(5y)4.7%
ROICexgc growth 3Y-30.81%
ROICexgc growth 5Y-24.6%
ROICexc growth 3Y-31.42%
ROICexc growth 5Y-41%
OM growth 3Y-36.8%
OM growth 5Y-45.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.12%
GM growth 5Y0%
F-Score5
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 1.46%
Cap/Sales 0.19%
Interest Coverage 250
Cash Conversion 46.07%
Profit Quality N/A
Current Ratio 1.9
Quick Ratio 1.66
Altman-Z 5.82
F-Score5
WACC9.16%
ROIC/WACC0.08
Cap/Depr(3y)1%
Cap/Depr(5y)1.92%
Cap/Sales(3y)0.13%
Cap/Sales(5y)0.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.14%
EPS 3Y45.76%
EPS 5Y6.21%
EPS Q2Q%12%
EPS Next Y-38.5%
EPS Next 2Y23.69%
EPS Next 3Y18.42%
EPS Next 5Y17.52%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y2.52%
Revenue growth 5Y6.68%
Sales Q2Q%21.48%
Revenue Next Year23.16%
Revenue Next 2Y20.6%
Revenue Next 3Y18.26%
Revenue Next 5Y14.29%
EBIT growth 1Y-87.66%
EBIT growth 3Y-35.2%
EBIT growth 5Y-41.44%
EBIT Next Year14.86%
EBIT Next 3Y40.14%
EBIT Next 5Y27.81%
FCF growth 1Y-73.14%
FCF growth 3Y-26.62%
FCF growth 5Y-19.37%
OCF growth 1Y-72.47%
OCF growth 3Y-26%
OCF growth 5Y-19.31%

SUPERNUS PHARMACEUTICALS INC / SUPN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SUPERNUS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 5 / 10 to SUPN.


What is the valuation status for SUPN stock?

ChartMill assigns a valuation rating of 4 / 10 to SUPERNUS PHARMACEUTICALS INC (SUPN). This can be considered as Fairly Valued.


How profitable is SUPERNUS PHARMACEUTICALS INC (SUPN) stock?

SUPERNUS PHARMACEUTICALS INC (SUPN) has a profitability rating of 5 / 10.


Can you provide the PE and PB ratios for SUPN stock?

The Price/Earnings (PE) ratio for SUPERNUS PHARMACEUTICALS INC (SUPN) is 15.89 and the Price/Book (PB) ratio is 2.75.


How financially healthy is SUPERNUS PHARMACEUTICALS INC?

The financial health rating of SUPERNUS PHARMACEUTICALS INC (SUPN) is 6 / 10.